Overview

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Dipeptidyl-Peptidase IV Inhibitors
Liraglutide